Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navepegritide in Adolescents With Achondroplasia
NCT06732895Phase 2Active, not recruiting
- Sponsor
- Ascendis Pharma
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of navepegritide in achondroplasia (ACH), sponsored by Ascendis Pharma. Started Dec 2024; status: active, not recruiting.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT06732895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732895.